12月20日,丹麦制药巨头诺和诺德公司(NVO)在美股盘前遭遇了股价的剧烈波动,一度暴跌超过20%。据知情者透露,这一突如其来的市场反应主要源于该公司公布的一项关于新药CagriSema的临床试验数据。数据显示,使用CagriSema治疗的试验患者在68周后体重减轻了22.7%,这一结果未能达到市场预期,从而引发了投资者的广泛担忧和抛售行为。CagriSema是诺和诺德开发的一种新型组合疗法,由...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.